Immunobiotics for treating early
Age-related Macular Degeneration (AMD)

Objective

Age-related Macular Degeneration (AMD) is a chronic, progressive, sight-threatening disease, caused by the damage of the macula, the small, central area of the retina. People with AMD have difficulty seeing colours, details and later, to read, to drive and to work. The disease causes significant social, medical, and economic burden. Its prevalence (hidden in early stage) is estimated more 8-10% in industrialized countries (EU, USA) for people over 40 years. However, neither screening method is proposed for the early detection of AMD nor its effective treatment has been approved yet. The multivitamin products, found on the market today, have provenly no efficiency to supress early stage AMD, and rather expensive compared to their low-effectiveness in treating advanced AMD. The objective of PRIMAVERA project is the commercialization of a new medical food for treatment of AMD supported by a multicenter clinical trial.

Our new and unique formula, PRIMAVERA, is based on immunobiotic compounds prepared by our innovative technology, and metabolic booster compounds. The new and unique formula will expectedly have benefits on both visual functions and retinal alterations life quality of senior population affected by early AMD. The success of the project will also promote the growth of our company.